VIDEO: ZUMA-12 study may produce ‘practice changing’ trial results
Click Here to Manage Email Alerts
CAR T-cell therapy can serve as a frontline treatment option for patients with high risk B-cell lymphomas with CD-19 CAR T-cells, according to a presentation from ASH Annual Meeting and Exposition.
ZUMA-12 evaluated CAR T-cell therapy as first-line therapy and its potential as a curative option in the frontline setting before receiving chemotherapy, according to Ryan Cassaday, MD, associate professor at University of Washington & Fred Hutchinson Cancer Research Center and attending physician at Seattle Cancer Care Alliance.
“When you think about using this very potent and exciting therapy that can provide potentially curative potential in patients with relapsed refractory disease, but in a population of patients that in theory have curative options in the frontline setting before any chemotherapy, it's a provocative, exciting and interesting study,” Cassaday told Healio in a video interview.
Collapse
Neelapu SS, et al. Abstract 405. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Read more about
Click Here to Manage Email Alerts